Amgen tops cost watchdog’s price gougers list based on ‘unfounded’ increases for Enbrel without meaningful data

In a top 10 ranking of the most egregious price gougers from 2019, Amgen’s Enbrel topped US cost watchdog ICER’s naughty list with “unfounded” markups that added as much as $403 million to the nation’s drug spend during that time. Price increases for some of pharma’s most popular drugs have…